Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0LBEGP
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
STRO-003
|
|||||
| Synonyms |
STRO003; STRO 003
Click to Show/Hide
|
|||||
| Organization |
Sutro Biopharma, Inc.
|
|||||
| Drug Status |
Clinical candidate
|
|||||
| Indication |
In total 2 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Clinical candidate
Lung cancer [ICD11:2C25]
Clinical candidate
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Antibody Name |
SP11285
|
Antibody Info | ||||
| Antigen Name |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1)
|
Antigen Info | ||||
| Payload Name |
Exatecan
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
SC3417
|
Linker Info | ||||
| Conjugate Type |
Site-specifically conjugated using strain promoted alkyne-azide cycloaddition (SPAAC) to form a stable, homogeneous ADC.
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.